Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.71 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.65 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.61 |
| ▸ | HTR1A | P08908 | 2/20 | 0.59 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.59 |
| ▸ | GSK3B | P49841 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3590279 | 0.84 | SIGMAR1 (0.58) | L3MBTL1SIGMAR1HRH3HTR1ASLC6A4 | |
| SCHEMBL3590302 | 0.83 | SIGMAR1 (0.69) | SIGMAR1HRH3HTR1ASLC6A4 | |
| SCHEMBL14878042 | 0.83 | SIGMAR1 (0.69) | SIGMAR1HRH3HTR1ASLC6A4 | |
| SCHEMBL12023880 | 0.81 | SIGMAR1 (0.75) | SIGMAR1HRH3HTR1ASLC6A4 | |
| SCHEMBL10499190 | 0.80 | SIGMAR1 (0.73) | SIGMAR1HRH3HTR1ASLC6A4 | |
| SCHEMBL15615362 | 0.79 | SIGMAR1 (0.67) | SIGMAR1HRH3HTR1ASLC6A4 | |
| SCHEMBL19189995 | 0.79 | SIGMAR1 (0.67) | SIGMAR1HRH3HTR1ASLC6A4 | |
| SCHEMBL9881343 | 0.78 | SIGMAR1 (0.65) | SIGMAR1HRH3HTR1ASLC6A4 | |
| SCHEMBL3590284 | 0.77 | SIGMAR1 (0.60) | SIGMAR1HRH3HTR1ASLC6A4 | |
| SCHEMBL29356024 | 0.77 | HRH3 (1.00) | L3MBTL1SIGMAR1HRH3SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8507528-B2 | 2-alkyl-indazole compounds for the treatment of certain cns-related disorders | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2013-08-13 | — | — | US | disclosed |
| EP-2099780-B1 | 2 -ALKYL- INDAZOLE COMPOUNDS FOR THE TREATMENT OF CERTAIN CNS-RELATED DISORDERS | ACRAF (IT) | 2013-01-09 | — | — | EP | disclosed |
| US-20100056573-A1 | 2-ALKYL-INDAZOLE COMPOUNDS FOR THE TREATMENT OF CERTAIN CNS-RELATED DISORDERS | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2010-03-04 | — | — | US | disclosed |
| EP-2099780-A1 | 2 -ALKYL- INDAZOLE COMPOUNDS FOR THE TREATMENT OF CERTAIN CNS-RELATED DISORDERS | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A. (IT) | 2009-09-16 | — | — | EP | disclosed |
| WO-2008061688-A1 | 2 -ALKYL- INDAZOLE COMPOUNDS FOR THE TREATMENT OF CERTAIN CNS-RELATED DISORDERS | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056573-A1 | 2-ALKYL-INDAZOLE COMPOUNDS FOR THE TREATMENT OF CERTAIN CNS-RELATED DISORDERS | CYP11B2, CYP1A2, INA | L3MBTL1 2729/4885SIGMAR1 1349/4885HRH3 348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.